SQA
GNMX

Simon Quick Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Simon Quick Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-39,774
Closed -$50K – 616
2017
Q3 		$50K Buy
39,774
+15,384
+63% +$19.7K 0.02% 271
2017
Q2 		$32K Hold
24,390
– – 0.02% 151
2017
Q1 		$45K Hold
24,390
– – 0.03% 163
2016
Q4 		$126K Buy
+24,390
New +$128K 0.09% 111

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Simon Quick Advisors's GNMX Position: Q4 2017 in Review

Simon Quick Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 39,774 shares — an estimated $50K sold.

Simon Quick Advisors first reported a position in GNMX in Q4 2016 and held it in 4 quarters. The position peaked at $126K in Q4 2016. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • Simon Quick Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • Simon Quick Advisors sold 39,774 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $50K.
  • Simon Quick Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2016 and held it in 4 quarters.
  • Simon Quick Advisors's Aevi Genomic Medicine Inc position peaked at $126K in Q4 2016.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on Simon Quick Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.